DR5在宫颈上皮内瘤变与宫颈癌中的表达及意义  

Expression and significance of DR5 in cervical intraepithelial neoplasia and carcinoma of the cervix

作　　者：牛保华[1] 刘广超[1] 马远方[1] 

机构地区：[1]河南大学细胞与分子免疫学实验室,河南开封475001

出　　处：《河南大学学报（医学版）》2010年第4期278-280,共3页Journal of Henan University:Medical Science

基　　金：河南省杰出人才创新基金(074200510014)

摘　　要：目的:探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)死亡受体5(DR5)在宫颈黏膜上皮内瘤变与宫颈癌中的表达及其意义。方法:应用免疫组织化学方法检测DR5在56例宫颈黏膜上皮内瘤变、54例宫颈癌、10例正常宫颈黏膜中的表达。结果:DR5在正常宫颈黏膜组织、宫颈黏膜上皮内瘤变与宫颈癌中的表达呈递增趋势(P<0.05),DR5在中、低分化癌中的表达高于高分化癌中的表达(P<0.05);DR5的表达与肿瘤的病理类型、患者的年龄因素无明显相关性(P>0.05)。结论:DR5可能与宫颈癌发生、发展有关,对TRAIL和DR5的功能性抗体的抗肿瘤临床应用有一定的指导意义。Objective： To investigate the expression and significance of TRAIL and DR5（death receptor 5 of TRAIL） in cervical intraepithelial neoplasia and carcinoma of the cervix.Methods： The expression of DR5 in 56 cases of cervical intraepithelial neoplasia,54 cases of carcinoma of the cervix and 10 cases of normal cervical mucosa were detected by immunohistochemical method.Results： The expression of DR5 increased from normal cervical mucosa,cervical intraepithelial neoplasia to carcinoma of the cervix（P0.05）.The increased expression of DR5 was observed in moderate and poor differentiation degree of carcinoma of the cervix compared to high differentiation degree（P0.05）.There were no significant differences in the histology type and age（P0.05）.Conclusion： DR5 may be correlated to the occurrence and the development of carcinoma of the cervix,and also provide potential instructive significance for future clinical application of TRAIL and TRAIL and antibody.

关 键 词：肿瘤坏死因子相关凋亡诱导配体 死亡受体 抗体 上皮内瘤变 宫颈癌 免疫组织化学 

分 类 号：R737.33[医药卫生—肿瘤]